Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
A Phase 2b, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints, causing pain, swelling, stiffness, and loss of function. Synovial fibroblasts play a key role in RA pathogenesis, with treatment-refractory patients demonstrating increased numbers of these cells. The goal of this study is to evaluate the safety and effectiveness of ABBV-2294 (a combination of ABBV-722 and upadacitinib) compared to each drug alone in treating moderately to severely active RA. The platform study will measure improvements in disease activity using the American College of Rheumatology (ACR) criteria, changes in disease activity scores, and quality of life measures.
ABBV-2294 is an investigational combination drug being developed for the treatment of moderately to severely active rheumatoid arthritis. This is a Phase 2b, randomized, double-blind platform study. In sub-study 1, participants are placed in 1 of 5 groups, called treatment arms. Each group receives a different treatment consisting of either ABBV-722 alone, upadacitinib alone, or various doses of ABBV-722 combined with upadacitinib. Adult participants with a diagnosis of moderately to severely active rheumatoid arthritis who have failed at least 1 prior biologic disease-modifying antirheumatic drug (bDMARD) will be enrolled. Around 250 participants will be enrolled in the study at multiple sites worldwide.
Participants will receive oral tablet doses of ABBV-2294 (combination of ABBV-722 and upadacitinib), ABBV-722 alone, or upadacitinib alone. The study comprises a 24-week Double-Blind Phase (Period 1) followed by an optional 52-week Blinded Long Term Extension Phase (Period 2), for a total treatment duration of up to 76 weeks. After completing treatment, participants will have a 30-day Follow-Up Period.
Participants will attend regular visits during the study at a hospital or clinic, including screening, baseline, and scheduled visits through Week 76, followed by a follow-up visit. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: ABBVIE CALL CENTER
- 전화번호: 844-663-3742
- 이메일: abbvieclinicaltrials@abbvie.com
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Documented clinical diagnosis of RA for >= 3 months and fulfills 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for Rheumatoid arthritis
- No clinically significant medical conditions that would interfere with study participation or compromise participant safety
- Willing and able to comply with procedures required in this Master Protocol and all actively enrolling substudies
- Female participants who are not pregnant or breastfeeding, with negative pregnancy tests at Screening and Baseline
Exclusion Criteria:
- Development of a major cardiovascular event (e.g., acute myocardial infarction, stroke) while on study treatment
- Serious infection (e.g., sepsis) which cannot be adequately controlled by anti-infective treatment
- Confirmed diagnosis of deep vein thrombosis, pulmonary embolus or arterial thrombosis
- Development of active tuberculosis at any time during the study
- Development of any malignancy except localized non-melanoma skin cancer or carcinoma in situ of the cervix
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: ABBV-2294 Dose A
Participants will receive co-administration of ABBV-722 and upadacitinib |
Oral Tablet Oral Tablet |
|
실험적: ABBV-2294 Dose B
Participants will receive co-administration of ABBV-722 and upadacitinib |
Oral Tablet Oral Tablet |
|
실험적: ABBV-2294 Dose C
Participants will receive co-administration of ABBV-722 and upadacitinib |
Oral Tablet Oral Tablet |
|
실험적: ABBV-722 Monotherapy
Participants will receive ABBV-722. At Week 12, participants will then be blindly switched to co-administration of ABBV-722 and upadacitinib. |
Oral Tablet |
|
활성 비교기: Upadacitinib Monotherapy
Participants will receive upadacitinib. |
Oral Tablet |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants Achieving ACR50 Response
기간: Week 12
|
The ACR50 response is defined as at least 50% improvement in the American College of Rheumatology (ACR) criteria for rheumatoid arthritis. The ACR50 response requires at least 50% improvement in tender and swollen joint counts and at least 50% improvement in at least 3 of the following 5 measures: patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function (HAQ-DI), and acute phase reactant (CRP or ESR). |
Week 12
|
|
Number of Participants Experiencing Adverse Events
기간: Up to 80 Weeks
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to 80 Weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants Achieving ACR20 Response
기간: Week 12
|
ACR20 response is defined as at least 20% improvement from Baseline in the American College of Rheumatology (ACR) core criteria, which includes tender joint count, swollen joint count, patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function, and acute phase reactant (C-reactive protein or erythrocyte sedimentation rate). |
Week 12
|
|
Percentage of Participants Achieving ACR70 Response
기간: Week 12
|
ACR70 response is defined as at least 70% improvement from Baseline in the American College of Rheumatology (ACR) core criteria, which includes tender joint count, swollen joint count, patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function, and acute phase reactant (C-reactive protein or erythrocyte sedimentation rate). |
Week 12
|
|
Percentage of Participants Achieving Low Disease Activity Based on DAS28 (CRP) <= 3.2
기간: Week 12
|
Low Disease Activity (LDA) is defined as a Disease Activity Score 28 using C-reactive protein (DAS28 [CRP]) of <= 3.2. DAS28 (CRP) is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and C-reactive protein. Scores range from 0 to approximately 10, with higher scores indicating more disease activity. |
Week 12
|
|
Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) < 2.6
기간: Week 12
|
Clinical Remission (CR) is defined as a Disease Activity Score 28 using C-reactive protein (DAS28 [CRP]) of < 2.6. DAS28 (CRP) is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and C-reactive protein. Scores range from 0 to approximately 10, with higher scores indicating more disease activity. |
Week 12
|
|
Percentage of Participants with a Change From Baseline in DAS28 (CRP)
기간: Baseline to Week 12
|
Disease Activity Score 28 using C-reactive protein (DAS28 [CRP]) is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and C-reactive protein. Scores range from 0 to approximately 10, with higher scores indicating more disease activity. A negative change from Baseline indicates improvement. |
Baseline to Week 12
|
|
Percentage of Participants Achieving Low Disease Activity Based on Clinical Disease Activity Index (CDAI) <= 10
기간: Week 12
|
Low Disease Activity (LDA) is defined as a Clinical Disease Activity Index (CDAI) of <= 10. CDAI is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76, with higher scores indicating more disease activity. |
Week 12
|
|
Percentage of Participants Achieving Clinical Remission Based on CDAI <= 2.8
기간: Week 12
|
Clinical Remission (CR) is defined as a Clinical Disease Activity Index (CDAI) of <= 2.8. CDAI is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76, with higher scores indicating more disease activity. |
Week 12
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: ABBVIE INC., AbbVie
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- M26-032
- 2026-526301-15-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 공유 기간
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD 공유 액세스 기준
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .